Danaher Co. (NYSE:DHR) Shares Acquired by Ballast Advisors LLC

Ballast Advisors LLC raised its position in Danaher Co. (NYSE:DHR) by 64.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 3,218 shares of the conglomerate’s stock after acquiring an additional 1,264 shares during the quarter. Ballast Advisors LLC’s holdings in Danaher were worth $744,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Banco Santander S.A. purchased a new stake in shares of Danaher during the 3rd quarter worth approximately $683,000. First Citizens Bank & Trust Co. grew its stake in shares of Danaher by 0.6% during the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after purchasing an additional 149 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in shares of Danaher by 48.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after acquiring an additional 96,395 shares during the period. Parkside Financial Bank & Trust grew its holdings in Danaher by 4.8% in the third quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock valued at $764,000 after purchasing an additional 142 shares during the last quarter. Finally, Keybank National Association OH increased its position in shares of Danaher by 0.5% in the third quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock valued at $137,238,000 after buying an additional 2,567 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Danaher news, Director Walter G. Lohr sold 3,289 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $251.15, for a total transaction of $826,032.35. Following the sale, the director now owns 14,129 shares of the company’s stock, valued at approximately $3,548,498.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Walter G. Lohr sold 3,289 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $251.15, for a total value of $826,032.35. Following the transaction, the director now directly owns 14,129 shares in the company, valued at $3,548,498.35. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock worth $8,265,802 in the last three months. Insiders own 11.10% of the company’s stock.

Danaher Stock Up 0.3 %

Shares of NYSE:DHR traded up $0.64 on Monday, reaching $240.59. The company had a trading volume of 515,490 shares, compared to its average volume of 2,663,663. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The stock has a 50-day moving average price of $249.71 and a 200 day moving average price of $229.90. The stock has a market capitalization of $178.17 billion, a P/E ratio of 37.60, a P/E/G ratio of 3.65 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.18. The firm had revenue of $6.41 billion during the quarter, compared to the consensus estimate of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The business’s revenue was down 10.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.87 EPS. On average, equities analysts expect that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a $0.27 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher’s payout ratio is presently 16.90%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Raymond James lifted their price objective on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Royal Bank of Canada increased their target price on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Barclays increased their price target on shares of Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research note on Wednesday, April 10th. KeyCorp raised their price objective on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Finally, JPMorgan Chase & Co. boosted their target price on Danaher from $250.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, December 20th. Seven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $267.43.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.